Eton Pharmaceuticals’ (ETON) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $11.00 target price on the stock.

Separately, Craig Hallum boosted their price objective on Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, October 28th.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ:ETON traded up $0.01 during trading on Wednesday, reaching $10.61. The stock had a trading volume of 46,622 shares, compared to its average volume of 92,112. The stock has a market capitalization of $274.12 million, a PE ratio of -48.18 and a beta of 1.25. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $11.11. The business’s 50-day moving average price is $7.17 and its 200 day moving average price is $4.90.

Insiders Place Their Bets

In related news, major shareholder Opaleye Management Inc. purchased 57,500 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was acquired at an average price of $4.65 per share, with a total value of $267,375.00. Following the completion of the acquisition, the insider now directly owns 2,660,000 shares in the company, valued at approximately $12,369,000. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders purchased 85,600 shares of company stock valued at $462,674. Insiders own 14.89% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Westside Investment Management Inc. boosted its stake in Eton Pharmaceuticals by 2.0% during the 2nd quarter. Westside Investment Management Inc. now owns 585,400 shares of the company’s stock worth $1,926,000 after acquiring an additional 11,440 shares during the last quarter. Acadian Asset Management LLC raised its stake in Eton Pharmaceuticals by 13.7% during the 1st quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after buying an additional 18,898 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after acquiring an additional 30,167 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after acquiring an additional 41,469 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $362,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.